TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 793705

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (ALG) treatment, 20 mg/kg-d intravenously for 10 days after transplantation
Number of subjects: 179

Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 179
Study: 31489831

Group type: EXPERIMENTAL
Intervention: Fathering Through Change (FTC) intervention
Number of subjects: 426

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 426
Study: 28375641

Group type: EXPERIMENTAL
Intervention: Curcumin and Boswellia serrata supplement
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 25935422

Group type: COMPARATOR
Intervention: Oxytocin 5U alone (Placebo)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxytocin 5U + Calcium Chloride 200mg (CA-200)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oxytocin 5U + Calcium Chloride 400mg (CA-400)
Number of subjects: 60
Study: 23548916

Group type: EXPERIMENTAL
Intervention: NeuroAiD II (MLC901)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22149470

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19567110

Group type: EXPERIMENTAL
Intervention: MRSA strains isolated from wounds caused by earthquake (subtypes A, B, C, E)
Number of subjects: 11

Group type: COMPARATOR
Intervention: MRSA strains isolated from non-earthquake-stricken areas (subtypes A, B, C, D)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Comparison of MRSA strains from earthquake and non-earthquake areas
Number of subjects: 11
Study: 16501682

Group type: EXPERIMENTAL
Intervention: Skin disorders prevalence
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Pigmentary disorders
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Dermatitis/eczema and related conditions
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Disorders of skin appendages
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Melanocytic nevi (MN)
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Post‐inflammatory pigmentation
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Scars
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Acne
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Dandruff
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Pediculosis capitis
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: Postinflammatory hyper/hypo pigmentation
Number of subjects: 2239

Group type: EXPERIMENTAL
Intervention: MN, dandruff, keratosis pilaris, acne, and folliculitis
Number of subjects: 2239
Study: 12738463

Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphate (45 ml at 7:00 PM, 45 ml 3 hours before colonoscopy)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tablet sodium phosphate (20 tablets at 7:00 PM, 20 tablets 3-5 hours before colonoscopy)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Liquid sodium phosphate
Number of subjects: 101

Group type: COMPARATOR
Intervention: Tablet sodium phosphate
Number of subjects: 101
Study: 11126465

Group type: EXPERIMENTAL
Intervention: YIPS
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control
Number of subjects: 75
Study: 9061218

Group type: EXPERIMENTAL
Intervention: Azelastine eye drops administered 30 min after ASCC
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Azelastine eye drops after 7 days of treatment, 30 min after ASCC
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8837422

Group type: EXPERIMENTAL
Intervention: Probiotic infant milk formula (IMF) containing Bifidobacterium sp. strain LW420
Number of subjects: 17

Group type: COMPARATOR
Intervention: Nonprobiotic infant milk formula (IMF)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both probiotic and nonprobiotic IMF
Number of subjects: 17
Study: 2674643

Group type: EXPERIMENTAL
Intervention: Mebendazole with sunflower oil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Mebendazole alone
Number of subjects: 86
Study: 1102976

Group type: EXPERIMENTAL
Intervention: Diet termination group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Diet continuation group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 31595627

Group type: EXPERIMENTAL
Intervention: Online self-help training (n = 130)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Care as usual (CAU; n = 132)
Number of subjects: 262
Study: 30383540

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: IL-17A response signature
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 28628488

Group type: EXPERIMENTAL
Intervention: Intensive, progressive strength and functional training intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low-intensity group training (Control)
Number of subjects: 110
Study: 25846715

Group type: EXPERIMENTAL
Intervention: d-AMPH 5 mg/70 kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: d-AMPH 10 mg/70 kg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: d-AMPH 20 mg/70 kg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23999449

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 233

Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 233
Study: 21224436

Group type: EXPERIMENTAL
Intervention: Intravenous ω‐3 polyunsaturated fatty acids (PUFAs) administered as a single dose of a lipid emulsion containing 4.1 g of ω‐3 PUFAs during HD
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (saline) administered during HD
Number of subjects: 44
Study: 19922249

Group type: EXPERIMENTAL
Intervention: Acem meditation (20 minutes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quiet rest condition (20 minutes)
Number of subjects: 0
Study: 16508584

Group type: EXPERIMENTAL
Intervention: Hormonal replacement therapy (HRT)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Turner syndrome (TS)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 8
Study: 15195756

Group type: EXPERIMENTAL
Intervention: 201Tl rest-redistribution SPECT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 18F-fluorodeoxyglucose SPECT
Number of subjects: 41
Study: 10886487

Group type: EXPERIMENTAL
Intervention: On-demand beta2-agonist inhalation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular beta2-agonist inhalation
Number of subjects: 80
Study: 9311207

Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 0.5 mmol.l‐1 of Mg2+ (Group II)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 1.0 mmol.l‐1 of Mg2+ (Group III)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 2.0 mmol.l‐1 of Mg2+ (Group IV)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Acetated Ringer solution containing 4.0 mmol.l‐1 of Mg2+ (Group V)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mg(2+)‐free acetated Ringer solution (Group I)
Number of subjects: 38
Study: 8451670

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (no beta-blockers)
Number of subjects: 6
Study: 2951828

Group type: EXPERIMENTAL
Intervention: Combination fenoterol/ipratropium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 20
Study: 30384941

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME) using hyrax appliances
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 30
Study: 26173589

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 55

Group type: COMPARATOR
Intervention: Active control (isometric squats on a vibration platform without vibration)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 55
Study: 23356833

Group type: EXPERIMENTAL
Intervention: Incobotulinum toxin A
Number of subjects: 112

Group type: COMPARATOR
Intervention: Onabotulinum toxin A
Number of subjects: 112
Study: 22401287

Group type: EXPERIMENTAL
Intervention: Double-pulse TMS applied to the left FEF during the Simon task (0-40 msec and 40-80 msec after stimulus onset)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double-pulse TMS applied to the right FEF during the Simon task (80-120 msec after stimulus onset)
Number of subjects: 0
Study: 20386123

Group type: EXPERIMENTAL
Intervention: Body mass countermovement jumps (CMJs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Body mass CMJs
Number of subjects: 20
Study: 18550933

Group type: EXPERIMENTAL
Intervention: Candesartan (angiotensin receptor blocker)
Number of subjects: 809

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 809
Study: 15820793

Group type: EXPERIMENTAL
Intervention: GnRH analogues and recombinant IL-2
Number of subjects: 24

Group type: COMPARATOR
Intervention: GnRH analogues without IL-2
Number of subjects: 24
Study: 12439649

Group type: EXPERIMENTAL
Intervention: 2512 kJ (600 kcal) daily energy deficit diet (ED)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 6279 kJ (1500 kcal) generalized low‐calorie diet (GLC)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Lean red meat included in diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Weight maintenance phase
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control period prior to dietary advice
Number of subjects: 122
Study: 10338454

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment (>/=24‐hour insulin‐glucose infusion followed by multidose subcutaneous insulin)
Number of subjects: 620

Group type: COMPARATOR
Intervention: Routine antidiabetic therapy (control group)
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 620

Group type: COMPARATOR
Intervention: Control group (routine antidiabetic therapy)
Number of subjects: 620
Study: 8881840

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 524
Study: 1782080

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (two monthly cycles of intravenous doxorubicin/cyclophosphamide/5‐fluorouracil before locoregional therapy and four cycles subsequently)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (six monthly cycles following locoregional therapy)
Number of subjects: 196
Study: 6184493

Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 100
Study: 30526001

Group type: EXPERIMENTAL
Intervention: In situ skills training (IST) only
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Program + IST
Number of subjects: 281

Group type: COMPARATOR
Intervention: Program only
Number of subjects: 281

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 281
Study: 27817918

Group type: EXPERIMENTAL
Intervention: Krill oil (945 mg/day EPA + 510 mg/day DHA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fish oil (1000 mg/day EPA + 500 mg/day DHA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (olive oil 1500 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Krill oil
Number of subjects: 60
Study: 27058408

Group type: EXPERIMENTAL
Intervention: Lung impedance (LI)‐guided treatment
Number of subjects: 256

Group type: COMPARATOR
Intervention: Clinical assessment (Control)
Number of subjects: 256
Study: 24494602

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 340

Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: both AL and ASAQ
Number of subjects: 340
Study: 22676398

Group type: EXPERIMENTAL
Intervention: Internet-based aftercare program (individualized self-monitoring module and weekly 90-min chat sessions)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 75
Study: 19401066

Group type: EXPERIMENTAL
Intervention: SSRI plus supportive care
Number of subjects: 220

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 220
Study: 17416108

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 x 3 g/24 hours
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ceftazidime divided into 6 administrations of 2 x 3 g/24 hours
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified dosing regimen (1 g x 6 administrations)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceftazidime clearance
Number of subjects: 30
Study: 15021446

Group type: EXPERIMENTAL
Intervention: Raloxifene + low-dose, transdermal estrogen (RLX+E)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Raloxifene + placebo (RLX+P)
Number of subjects: 60
Study: 11403120

Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 6 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Creatine supplementation for 34 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 14
Study: 9552032

Group type: EXPERIMENTAL
Intervention: Simultaneous radiotherapy plus chemotherapy (arm B)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 270
Study: 7925193

Group type: EXPERIMENTAL
Intervention: 10 mg succimer/kg body wt
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg succimer/kg body wt
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 12
Study: 3051392

Group type: EXPERIMENTAL
Intervention: Dietary omega-3 fatty acids from fish and fish oil
Number of subjects: 68
Study: 30246910

Group type: EXPERIMENTAL
Intervention: Emollient containing lactic acid and refined almond oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emollient containing lactic acid, refined almond oil, and polidocanol
Number of subjects: 0
Study: 28837002

Group type: EXPERIMENTAL
Intervention: Probiotic milk consumption (Lactobacillus rhamnosus GG, Bifidobacterium animalis subsp. lactis Bb‐12, Lactobacillus acidophilus La‐5) during and after pregnancy
Number of subjects: 298
Study: 24939868

Group type: EXPERIMENTAL
Intervention: Local sinusoidal extremely low frequency magnetic field (LSELF‐MF) exposure at 45 Hz-360 µT
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional neurofeedback (NF) without LSELF‐MF exposure
Number of subjects: 24
Study: 24500553

Group type: EXPERIMENTAL
Intervention: Prescriptive exercise
Number of subjects: 0
Study: 21156715

Group type: COMPARATOR
Intervention: Online educational training for VTE prophylaxis
Number of subjects: 67
Study: 18802744

Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 70

Group type: COMPARATOR
Intervention: GnRH agonist
Number of subjects: 70
Study: 16958290

Group type: EXPERIMENTAL
Intervention: Flowable composite
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: everStick NET (glass fiber)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ribbond THM (polyethylene fiber)
Number of subjects: 24
Study: 15193474

Group type: EXPERIMENTAL
Intervention: Natural-cycle IVF
Number of subjects: 129

Group type: COMPARATOR
Intervention: Controlled ovarian hyperstimulation with microdose GnRH analog flare
Number of subjects: 129
Study: 11509512

Group type: EXPERIMENTAL
Intervention: 12‐wk standard hospital rehabilitation program supplemented with an exercise training program (n = 19)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Home‐based rehabilitation program without exercise (n = 16)
Number of subjects: 35
Study: 9678091

Group type: EXPERIMENTAL
Intervention: Triphasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Number of subjects: 56

Group type: COMPARATOR
Intervention: Monophasic oral contraceptive (OC) containing ethinylestradiol and gestodene
Number of subjects: 56
Study: 8510082

Group type: EXPERIMENTAL
Intervention: LAM 100 (Marshall F-88)
Number of subjects: 40

Group type: COMPARATOR
Intervention: random zero sphygmomanometer
Number of subjects: 40

Group type: COMPARATOR
Intervention: Finapres
Number of subjects: 40
Study: 2961938

Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 240

Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 240
Study: 31637452

Group type: EXPERIMENTAL
Intervention: Active cannabis (12.5% THC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo (<0.1% THC)
Number of subjects: 91
Study: 29142143

Group type: EXPERIMENTAL
Intervention: DHA 2 g/day
Number of subjects: 240

Group type: COMPARATOR
Intervention: Corn oil (placebo)
Number of subjects: 240
Study: 28758692

Group type: EXPERIMENTAL
Intervention: Three-session intervention targeting perfectionism
Number of subjects: 212

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 212
Study: 25698079

Group type: EXPERIMENTAL
Intervention: Negative mood condition (CS+ with chocolate mousse intake)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral mood condition (CS+ with chocolate mousse intake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood condition (CS- without chocolate mousse intake)
Number of subjects: 0
Study: 23628696

Group type: EXPERIMENTAL
Intervention: Inhibitory control challenging condition (experimental)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control condition (inhibitory control not challenged)
Number of subjects: 33
Study: 19793768

Group type: EXPERIMENTAL
Intervention: 4 weeks in-hospital exercise training (6 x 15 min bicycle/day, 5 days/week) and a hypocaloric diet, followed by a 5 months ambulatory program (30 min ergometer/day, 5 days/week, plus 1 h group exercise/week)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 4 weeks in-hospital exercise training and hypocaloric diet
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 18377250

Group type: EXPERIMENTAL
Intervention: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks, targeted by functional imaging at approximately 50% of motor movement threshold.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy without CS) for 6 weeks.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cortical stimulation (CS) delivered concurrently with rehabilitation therapy for 6 weeks.
Number of subjects: 24
Study: 16670135

Group type: EXPERIMENTAL
Intervention: 10 mg of ramipril once daily for 24 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 14595183

Group type: EXPERIMENTAL
Intervention: Dolasetron 50 mg
Number of subjects: 71

Group type: COMPARATOR
Intervention: Droperidol 1 mg
Number of subjects: 71
Study: 10381288

Group type: EXPERIMENTAL
Intervention: Unstable angina pectoris patients
Number of subjects: 31
Study: 8887699

Group type: EXPERIMENTAL
Intervention: DIET program (computer‐presented health education package)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo computer‐based program
Number of subjects: 54
Study: 2064881

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6337558

Group type: EXPERIMENTAL
Intervention: UV-B radiation (six daily treatments of one minimal erythemal dose (MErD) prior to starting daily applications of a 0.02% mechlorethamine ointment and thereafter one MErD weekly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical applications of mechlorethamine (0.02% ointment) without UV-B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UV-B radiation
Number of subjects: 0
Study: 31479007

Group type: EXPERIMENTAL
Intervention: Exercise training intervention (150 minutes of moderate intensity aerobic activity and two days of resistance training per week for 5 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information only control group (monthly newsletters on type 2 diabetes education and prevention)
Number of subjects: 0
Study: 29749323

Group type: EXPERIMENTAL
Intervention: δ-tocotrienol (300 mg twice daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 27400468

Group type: EXPERIMENTAL
Intervention: Acupuncture dredging liver and regulating flow of theosophy (group 1)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Acupoint shallow stab (group 2)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Non-acupoint shallow stab (group 3)
Number of subjects: 163
Study: 24524367

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a (IFNβ1a) 22 mcg subcutaneous injection three times per week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22188162

Group type: EXPERIMENTAL
Intervention: Hybrid instrumentation technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Manual instrumentation technique
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nickel-titanium (NiTi) rotary instrumentation technique
Number of subjects: 15

Group type: COMPARATOR
Intervention: All techniques tested
Number of subjects: 15
Study: 20308220

Group type: EXPERIMENTAL
Intervention: Discussion of sexual activity at preventive care visits
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Identification of adolescents with high-risk behaviors
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Prescription of condoms
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Distribution of condoms
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Condom demonstrations
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Recommendation for STI tests
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Recommendation for HIV testing
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Barriers to HIV and STI prevention counseling
Number of subjects: 468
Study: 18173156

Group type: EXPERIMENTAL
Intervention: Electric acupuncture (EA) at Sishencong (EX‐HN 1)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Oral administration of Tianmeng Capsule (Control)
Number of subjects: 276
Study: 15804995

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ondansetron (5 mg/m2) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Orally disintegrating tablet (ODT) ondansetron (4-8 mg according to body surface area) administered 30 min before chemotherapy and 12 hourly after chemotherapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: IV ondansetron
Number of subjects: 22

Group type: COMPARATOR
Intervention: ODT ondansetron
Number of subjects: 22